Two novel anticancer compounds with minimum cardiotoxic property

Area of Science:

• Medicinal Chemistry
• Cardiovascular Pharmacology
• Cancer Therapeutics

Background:

• Two novel tri-aryl compounds exhibit potent anti-breast cancer activity.
• Concerns exist regarding the cardiotoxicity of these compounds due to their mechanism of action.
• H9c2 cardiomyocytes serve as an in vitro model for assessing cardiotoxicity.

Purpose of the Study:

• To evaluate the cardiotoxicity of two novel anti-breast cancer compounds.
• To determine the safety profile of these compounds on H9c2 cardiomyocytes.
• To elucidate the mechanism underlying any observed cardiotoxicity.

Main Methods:

• Cytotoxic effects were assessed using MTT assay on H9c2 cells.
• Apoptosis and necrosis were evaluated via Annexin V/PI staining.
• Intracellular reactive oxygen species (ROS) and mitochondrial membrane potential were measured using flow cytometry.

Main Results:

• Cardiotoxicity was concentration- and time-dependent.
• No significant apoptosis or necrosis was observed at effective anti-cancer concentrations (10 μM).
• Higher concentrations induced cell death through ROS-mediated mitochondrial dysfunction, while therapeutic doses showed no cardiotoxic effects.

Conclusions:

• The novel compounds demonstrate anti-breast cancer efficacy with a favorable cardiac safety profile at therapeutic concentrations.
• The findings suggest a low risk of cardiotoxicity for these compounds in treating breast cancer.
• Further investigation into the dose-dependent effects on mitochondrial function is warranted.